Get started
Author

Barbara Eichhorst

Observed name: B Eichhorst
ORCID: 0000-0001-9990-6918
Observed ORCID: 0000-0001-9990-6918
OpenAlex ID: A5113350033
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
2024 · Othman Al-Sawaf, Sandra Robrecht, et al. · Blood · 154
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 · Jennifer R. Brown, John F. Seymour, et al. · New England Journal of Medicine · 127
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
2025 · Othman Al-Sawaf, Janina Stumpf, et al. · New England Journal of Medicine · 59
International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations
2025 · Adam S. Kittai, Monia Marchetti, et al. · Blood · 26
PDF
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia
2026 · Othman Al-Sawaf, Benjamin N. Locher, et al. · Blood · 14
CLL-280 Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial
2024 · Arnon P. Kater, Ann Janssens, et al. · Clinical Lymphoma Myeloma & Leukemia · 12
When and How Long to Treat Chronic Lymphocytic Leukemia?
2025 · Carsten U. Niemann, Abraham Varghese, et al. · American Society of Clinical Oncology Educational Book · 8
PDF
CLL-984: CLL18/MOIRAI International Phase 3 Trial: Aiming to Establish Measurement of Individual Residual Disease for Adjustment of Treatment Duration to Improve Outcomes in First-Line Treatment of CLL/SLL
2025 · Léa Mazot, Ellinor Görgen, et al. · Clinical Lymphoma Myeloma & Leukemia · 4
Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial
2025 · Othman Al-Sawaf, Janina Stumpf, et al. · Blood · 3
PDF
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study
2025 · Andrea Visentin, Enrico Gaffo, et al. · Leukemia · 2
PDF
Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial
2024 · Arnon P. Kater, Ann Janssens, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial
2026 · Armin Riecke, Sandra Robrecht, et al. · Blood · 1
Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY
2025 · Paolo Ghia, Barbara Eichhorst, et al. · Blood · 1
PDF
Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study
2025 · Eleonora Roncaglia, Enrico Gaffo, et al. · Journal of Hematology & Oncology · 1
PDF
Efficacy and safety of nemtabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Cohort J of the phase 2 BELLWAVE-003 study.
2025 · Thomas Kipps, Farrukh Tauseef Awan, et al. · Journal of Clinical Oncology · 1
PDF
Hämatologie 2008
2008 · P Borchmann, B Eichhorst, et al. · DMW - Deutsche Medizinische Wochenschrift · 1
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy
2026 · Othman Al-Sawaf, Can Zhang, et al. · Journal of Clinical Oncology
PDF
Chronic lymphocytic leukemia with IGH :: BCL3 ‐translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape
2026 · Cosima Drewes, Cristina López, et al. · HemaSphere
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia
2026 · Cosima Drewes, Cristina López, et al. · Leukemia
PDF
Transition Into Clinical Routine and Survival Outcomes of BCL2 ‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry
2026 · Nadine Kutsch, Rudy Ligtvoet, et al. · European Journal Of Haematology
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia
2026 · Florian Simon, Rudy Ligtvoet, et al. · Leukemia & lymphoma/Leukemia and lymphoma
Single recipient cell tracking of tellurium-labeled extracellular vesicle proteomes (TeLEV) identifies EV-driven immunomodulation
2025 · Daniel Bachurski, Rahil Gholamipoorfard, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies
2025 · Marwan Kwok, Connor Johnson, et al. · Blood
POSTER: CLL-984 CLL18/MOIRAI International Phase 3 Trial: Aiming to Establish Measurement of Individual Residual Disease for Adjustment of Treatment Duration to Improve Outcomes in First-Line Treatment of CLL/SLL
2025 · Léa Mazot, Ellinor Görgen, et al. · Clinical Lymphoma Myeloma & Leukemia
Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG)
2024 · Ellinor Goergen, Julia v. Tresckow, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 26
Citation count: 415
H-index: 7
I10-index: 6
Year
Topic
Type